Advansource Biomaterials Corp (ASNB) financial statements (2020 and earlier)

Company profile

Business Address 229 ANDOVER STREET
WILMINGTON, MA 01887
State of Incorp. DE
Fiscal Year End March 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
3/31/2018
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0446093143124120
Cash and cash equivalents0446093143124120
Receivables000    
Inventory, net of allowances, customer advances and progress billings000242300340297
Inventory000242300340297
Prepaid expense000    
Other undisclosed current assets0(445)0681479413574
Total current assets:1111,016922877991
Noncurrent Assets
Property, plant and equipment2221,8051,8181,8341,823
Deposits noncurrent assets000    
Other undisclosed noncurrent assets000101103104106
Total noncurrent assets:2221,9061,9211,9381,929
TOTAL ASSETS:3332,9222,8432,8152,920
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities111    
Accounts payable010    
Accrued liabilities000    
Customer advances and deposits243243297295
Other undisclosed current liabilities000937991952967
Total current liabilities:1111,1801,2341,2491,262
Noncurrent Liabilities
Other undisclosed noncurrent liabilities2222,1582,1592,1602,161
Total noncurrent liabilities:2222,1582,1592,1602,161
Total liabilities:3333,3383,3933,4093,423
Stockholders' equity
Stockholders' equity attributable to parent, including:(0)(0)(0)(416)(550)(594)(503)
Common stock00021212121
Treasury stock, value   30303030
Additional paid in capital38383838,42338,42338,40438,404
Accumulated deficit(38)(38)(39)(38,830)(38,964)(38,989)(38,898)
Other undisclosed stockholders' equity attributable to parent   (60)(60)(60)(60)
Other undisclosed stockholders' equity(0)(0)(0)    
Total stockholders' equity:(0)(0)(0)(416)(550)(594)(503)
TOTAL LIABILITIES AND EQUITY:3332,9222,8432,8152,920

Income statement (P&L) ($ in thousands)

9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
3/31/2018
Q4
Revenues7631(2,269)889794589930
Revenue, net580589930
Cost of revenue
(Cost of Goods and Services Sold)
(192)(0)669(259)(239)(173)(196)
Gross profit:5711(1,600)630555416734
Operating expenses(419)(0)1,250(402)(436)(413)(382)
Operating income (loss):1520(349)2281193352
Nonoperating income
(Investment Income, Nonoperating)
2490     
Interest and debt expense1400282(94)(94)(94)(94)
Other undisclosed income from continuing operations before equity method investments, income taxes  1    
Income (loss) from continuing operations before equity method investments, income taxes:5410(66)13425(91)258
Other undisclosed loss from continuing operations before income taxes(529)(0)(2)    
Income (loss) before gain (loss) on sale of properties:120(68)13425(91)258
Other undisclosed net income 83     
Net income (loss) available to common stockholders, diluted:1283(68)13425(91)258

Comprehensive Income ($ in thousands)

9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
3/31/2018
Q4
Net income (loss):1283(68)13425(91)258
Comprehensive income (loss), net of tax, attributable to parent:1283(68)13425(91)258

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: